Site-specific tissue inhibitor of metalloproteinase-1 governs the matrix metalloproteinases-dependent degradation of crosslinked collagen scaffolds and is correlated with interleukin-10

Journal of Tissue Engineering and Regenerative Medicine

Volumn 5, Issue 4, 2011, Pages 264-274

  Ye, Q ^a,b   van Amerongen, M J ^a   Sandham, J A ^c   Bank, R A ^a   van Luyn, M J A ^a   Harmsen, M C ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c JAMES COOK UNIVERSITY   (Australia)

Author keywords

Collagen scaffold; Degradation; Foreign body reaction; Interleukin 10; Matrix metalloproteinase; Tissue inhibitors of metalloproteinase

Indexed keywords

BIOMATERIALS; BLOOD VESSELS; COLLAGEN; ENZYME INHIBITION; SCAFFOLDS (BIOLOGY);

COLLAGEN SCAFFOLDS; COLLAGEN TYPE I; CROSSLINKED; FOREIGN BODY REACTIONS; IMPLANTATION SITES; INTERLEUKIN-10; MATRIX; MATRIX METALLOPROTEINASE; METALLOPROTEINASES; TISSUE INHIBITOR OF METALLOPROTEINASES;

TISSUE;

COLLAGEN; COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERLEUKIN 10; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE SCAFFOLD;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ENZYME DEGRADATION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 79952758009     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.311     Document Type: Article

References (37)

1. Brinckerhoff CE, Matrisian LM. 2002; Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3(3): 207-214.
2. Cao J, Drews M, Lee HM, et al. 1998; The propeptide domain of membrane type 1 matrix metalloproteinase is required for binding of tissue inhibitor of metalloproteinases and for activation of pro-gelatinase A. J Biol Chem 273(52): 34745-34752.
3. Cao J, Drews M, Lee HM, et al. 1999; The 9 kDa N-terminal propeptide domain of MT1-MMP is required for the activation of progelatinase A. Ann N Y Acad Sci 878: 710-712.
4. Cao J, Rehemtulla A, Pavlaki M, et al. 2005; Furin directly cleaves proMMP-2 in the trans-Golgi network resulting in a nonfunctioning proteinase. J Biol Chem 280(12): 10974-10980.
5. Cummings CL, Gawlitta D, Nerem RM, et al. 2004; Properties of engineered vascular constructs made from collagen, fibrin, and collagen-fibrin mixtures. Biomaterials 25(17): 3699-3706.
6. Daamen WF, Nillesen ST, Hafmans T, et al. 2005; Tissue response of defined collagen-elastin scaffolds in young and adult rats with special attention to calcification. Biomaterials 26(1): 81-92.
7. Hedrick MH, Daniels EJ. 2003; The use of adult stem cells in regenerative medicine. Clin Plast Surg 30(4): 499-505.
8. Hutmacher DW, Schantz T, Zein I, et al. 2001; Mechanical properties and cell cultural response of polycaprolactone scaffolds designed and fabricated via fused deposition modeling. J Biomed Mater Res 55(2): 203-216.
9. Jones G, Riley G. 2005; ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis. Arthritis Res Therapy 7(4): 160-169.
10. Jones JA, McNally AK, Chang DT, et al. 2008; Matrix metalloproteinases and their inhibitors in the foreign body reaction on biomaterials. J Biomed Mater Res A 84(1): 158-166.
11. Khouw IM, van Wachem PB, de Leij LF, et al. 1998; Inhibition of the tissue reaction to a biodegradable biomaterial by monoclonal antibodies to IFN-γ. J Biomed Mater Res 41(2): 202-210.
12. Khouw IM, van Wachem PB, van der Worp RJ, et al. 2000; Systemic anti-IFN-γ treatment and role of macrophage subsets in the foreign body reaction to dermal sheep collagen in rats. J Biomed Mater Res 49(3): 297-304.
13. Kyriakides TR, Bornstein P. 2003; Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost 90(6): 986-992.
14. Kyriakides TR, Foster MJ, Keeney GE, et al. 2004; The CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation. Am J Pathol 165(6): 2157-2166.
15. Lacraz S, Nicod LP, Chicheportiche R, et al. 1995; IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 96(5): 2304-2310.
16. Luttikhuizen DT, Harmsen MC, van Luyn MJ. 2006a; Cellular and molecular dynamics in the foreign body reaction. Tissue Eng 12(7): 1955-1970.
17. Luttikhuizen DT, Harmsen MC, van Luyn MJ. 2007; Cytokine and chemokine dynamics differ between rats and mice after collagen implantation. J Tissue Eng Regen Med 1(5): 398-405.
18. Luttikhuizen DT, van Amerongen MJ, de Feijter PC, et al. 2006b; The correlation between difference in foreign body reaction between implant locations and cytokine and MMP expression. Biomaterials 27(34): 5763-5770.
19. Mason C. 2007; Regenerative medicine. The industry comes of age. Med Device Technol 18(2): 25-30.
20. Mather ML, Morgan SP, Crowe JA. 2007; Meeting the needs of monitoring in tissue engineering. Regen Med 2(2): 145-160.
21. Mohamed MM, Sloane BF. 2006; Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6(10): 764-775.
22. Mostafa ME, Chollet-Martin S, Oudghiri M, et al. 2001; Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovasc Res 49(4): 882-890.
23. Munirah S, Kim SH, Ruszymah BH, et al. 2008; The use of fibrin and poly(lactic-co-glycolic acid) hybrid scaffold for articular cartilage tissue engineering: an in vivo analysis. Eur Cell Mater 15: 41-52.
24. Nagase H, Woessner JF Jr. 1999; Matrix metalloproteinases. J Biol Chem 274(31): 21491-21494.
25. Nuttall RK, Sampieri CL, Pennington CJ, et al. 2004; Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett 563(1-3): 129-134.
26. Paquette JS, Moulin V, Tremblay P, et al. 2004; Tissue-engineered human asthmatic bronchial equivalents. Eur Cell Mater 7: 1-11.
27. Petersen T, Niklason L. 2007; Cellular lifespan and regenerative medicine. Biomaterials 28(26): 3751-3756.
28. Popi AF, Lopes JD, Mariano M. 2004; Interleukin-10 secreted by B-1 cells modulates the phagocytic activity of murine macrophages in vitro. Immunology 113(3): 348-354.
29. Rivron NC, Liu JJ, Rouwkema J, et al. 2008; Engineering vascularised tissues in vitro. Eur Cell Mater 15: 27-40.
30. Sachlos E, Czernuszka JT. 2003; Making tissue engineering scaffolds work. Review: the application of solid freeform fabrication technology to the production of tissue engineering scaffolds. Eur Cell Mater 5: 29-39.
31. Sachlos E, Gotora D, Czernuszka JT. 2006; Collagen scaffolds reinforced with biomimetic composite nano-sized carbonate-substituted hydroxyapatite crystals and shaped by rapid prototyping to contain internal microchannels. Tissue Eng 12(9): 2479-2487.
32. Sternlicht MD, Werb Z. 2001; How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463-516.
33. Strongin AY, Collier I, Bannikov G, et al. 1995; Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270(10): 5331-5338.
34. Tai H, Mather ML, Howard D, et al. 2007; Control of pore size and structure of tissue engineering scaffolds produced by supercritical fluid processing. Eur Cell Mater 14: 64-77.
35. Tziakas DN, Chalikias GK, Hatzinikolaou HI, et al. 2003; Anti-inflammatory cytokine profile in acute coronary syndromes: behavior of interleukin-10 in association with serum metalloproteinases and proinflammatory cytokines. Int J Cardiol 92(2-3): 169-175.
36. van Amerongen MJ, Harmsen MC, Petersen AH, et al. 2006; The enzymatic degradation of scaffolds and their replacement by vascularized extracellular matrix in the murine myocardium. Biomaterials 27(10): 2247-2257.
37. Wahl DA, Sachlos E, Liu C, Czernuszka JT. 2007; Controlling the processing of collagen-hydroxyapatite scaffolds for bone tissue engineering. J Mater Sci Mater Med 18(2): 201-209.